Abstract
A NTITHYMOCYTE globulin (ATG) is used as an immunosuppressive drug for treating allograft rejection and as a prophylactic agent, preventing occurrence of rejection. Several products are available on the market,“’ and we have been using two of these, ATG Fresenius (ATG F) and ATG Merieux (ATG M), for many years at our institution. Questions regarding safety, efficacy, and reliability led us to test these two rabbit ATG products in a randomized trial of patients receiving ATG as prophylaxis, either due to risk factors or acute tubular necrosis (ATN). This report summarizes the study of 90 randomized patients receiving ATG after renal transplantation at our institution. Safety aspects, infectious complications, rejection frequency, and patient and graft survival were all studied.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
